# US 2012/0251491 A1 · Fused tricyclic aryl compounds useful for the treatment of viral diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251491 A1
- Document ID: US20120251491A1
- Status: Published application
- Kind: A1
- Application number: 13/320,427
- Filed: 2010-05-12
- Published: 2012-10-04
- Earliest claimed: 2009-05-12
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Stuart B. Rosenblum; Kevin X. Chen; Joseph A. Kozlowski; F. George Njoroge; Craig A. Coburn
- Web page: https://patentgrep.com/patent/US20120251491A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 403/04: having side-chains substituted by halogen atoms
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/044: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.

## Claims

### Claim 1

A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein each dotted line represents an optional and additional bond, such that only one optional and additional bond can be attached to each of Y1 and Y2, and wherein:
A is 4 to 7-membered heterocycloalkyl, 4 to 7-membered heterocycloalkenyl, aryl or heteroaryl, wherein said aryl group can be substituted with up to two R3 groups, which can be the same or different, and wherein said 4 to 7-membered heterocycloalkyl group, said 4 to 7-membered heterocycloalkenyl group or said heteroaryl group can be optionally and independently substituted on one or more ring nitrogen atoms with R1 and on one or more ring carbon atoms with R3;
D is 4 to 7-membered heterocycloalkyl, 4 to 7-membered heterocycloalkenyl, aryl or heteroaryl, wherein said aryl group can be substituted with up to two R4 groups, which can be the same or different, and wherein said 4 to 7-membered heterocycloalkyl group, said 4 to 7-membered heterocycloalkenyl group, or said heteroaryl group can be optionally and independently substituted on one or more ring nitrogen atoms with R2 and on one or more ring carbon atoms with R4;
L1 is a bond, —[C(R13)2]q—, —[C(R13)2]m—C(R13)═C(R13)—[C(R13)2]m—, —[C(R13)2]m—(C≡C)q—[C(R13)2]m—, —[C(R13)2]m—O—[C(R13)2]m—, —[C(R13)2]m—N(R14)—[C(R13)2]m—, —[C(R13)2]m—C(O)N(R14)—[C(R13)2]m—, —[C(R13)2]m—N(R14)C(O)—[C(R13)2]m—, —OC(O)N(R14)—, —N(R14)C(O)O—, —N(R14)C(O)N(R14)—, —[C(R13)2]mS(O)2[C(R13)2]m—, —S(O)2N(R14) [C(R13)2]m—, —[C(R13)2]mN(R14)S(O)2— or —N(R14)S(O)2N(R14)—, —C(O)—, —CF2—, such that when L1 is linked to a ring nitrogen atom of A, then L1 is joined via one of its carbon atoms;
L2 is a bond, —[C(R13)2]q—, —[C(R13)2]m—C(R13)═C(R13)—[C(R13)2]m—, —[C(R13)2]m—(C≡C)q—[C(R13)2]m—, —[C(R13)2]m—O—[C(R13)2]m—, —[C(R13)2]m—N(R14)—[C(R13)2]m—, —[C(R13)2]m—C(O)NR14)—[C(R13)2]m—, —[C(R13)2]m—N(R14)C(O)—[C(R13)2]m—, —OC(O)N(R14)—, —N(R14)C(O)O—, —N(R14)C(O)N(R14)—, —[C(R13)2]mS(O)2[C(R13)2]m—, —S(O)2N(R14) [C(R13)2]m—, —[C(R13)2]mN(R14)S(O)2— or —N(R14)S(O)2N(R14)—, —C(O)—, —CF2—, such that when L2 is linked to a ring nitrogen atom of D, then L2 is joined via one of its carbon atoms;
M1 is —C(R17)— or —N—;
M2 is —C(R17)— or —N—;
X1 is —[(R12)]q—, —C(R12)═C(R12)—, —N═C(R12)—, —C(R12)═N—, [C(R12)]nO—[(R12)]n—, [C(R12)]nN(R10)[C(R12)]n—, —N(R10)C(O)N(R10)—, —[C(R12)]nS(O)n[C(R12)]n—, —S(O)2N(R10)—, or —N(R10)S(O)2— when the optional and additional bond to X1 is not present, and X1 is —C(R12)— or —N— when the optional and additional bond to X1 is present;
X2 is —[C(R12)]q—, —C(R12)═C(R12)═C(R12)—, —N═C(R12)—, —C(R12)═N, —[C(R12)]nO—[C(R12)]n—, —[C(R12)]nN(R10)[C(R12)]n—, —N(R10)C(O)N(R10)—, —[C(R12)]nS(O)n[C(R12)]n—, —S(O)2N(R10)—, or —N(R10)S(O)2— when the optional and additional bond to X2 is not present, and X2 is —C(R12)— or —N— when the optional and additional bond to X2 is present;
Y1 is —C— when an optional and additional bond to Y1 is present, and Y1 is —CH— when an optional and additional bond to Y1 is absent;
Y2 is —C— when an optional and additional bond to Y2 is present, and Y2 is —CH— when an optional and additional bond to Y2 is absent;
Z1 is —[C(R12)]q—, —C(R12)═C(R12)—, —N═C(R12)—, —C(R12)═N—, —[C(R12)]nO—[C(R12)]n—, —[C(R12)]nN(R10)[C(R12)]n—, —N(R10)C(O)N(R10)—, —[C(R12)]nS(O)n[C(R12)]n—, —S(O)2N(R10)—, or —N(R10)S(O)2— when the optional and additional bond to Z1 is not present, and Z1 is —C(R12)— or —N— when the optional and additional bond to Z1 is present; such that the ring containing variables X1, Y1 and Z1 has from 5 to 8 ring atoms;
Z2 is —[C(R12)]q—, —C(R12)═C(R12)—, —N═C(R12)—, —C(R12)═N—, —[C(R12)]nO—[C(R12)]n—, —[C(R12)]nN(R10)[C(R12)]n—, —N(R10)C(O)N(R10)—, —[C(R12)]nS(O)n[C(R12)]n—, —S(O)2N(R10)—, or —N(R10)S(O)2— when the optional and additional bond to Z2 is not present, and Z2 is —C(R12)— or —N— when the optional and additional bond to Z2 is present; such that the ring containing variables X2, Y2 and Z2 has from 5 to 8 ring atoms;
each occurrence of R1 is independently —R5, —C1-C6 alkyl, —C1-C6 haloalkyl, —[C(R12)2]p-(3 to 7-membered cycloalkyl) or —[C(R12)2]p-(4 to 7-membered heterocycloalkyl), wherein said C1-C6 alkyl group, said C1-C6 haloalkyl group, said 3 to 7-membered cycloalkyl group or said 4 to 7-membered heterocycloalkyl group can be optionally and independently substituted with up to two R5 groups;
each occurrence of R2 is independently —R5, —C1-C6 alkyl, —C1-C6 haloalkyl, —[C(R12)2]p—(3 to 7-membered cycloalkyl) or —[C(R12)2]p-(4 to 7-membered heterocycloalkyl), wherein said C1-C6 alkyl group, said C1-C6 haloalkyl group, said 3 to 7-membered cycloalkyl group or said 4 to 7-membered heterocycloalkyl group can be optionally and independently substituted with up to two R5 groups;
each occurrence of R3 is independently —R5, —[C(R12)2]p—R5, —[C(R12)2]pOR5, —[C(R12)2]pOC(O)R5, —[C(R12)2]pN(R10)R5, —[C(R12)2]p-(3 to 7-membered cycloalkyl), —[C(R12)2]p-(3 to 7-membered heterocycloalkyl), —[C(R12)2]p-aryl or —[C(R12)2]p-heteroaryl, wherein said 3 to 7-membered cycloalkyl group, said 3 to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to four R5 groups, such that two R5 groups on different carbon atoms of the same R3 group can combine to form a C1-C3 alkylene group between the carbon atoms to which the two said R5 groups are attached, and wherein said 3 to 7-membered cycloalkyl group and said 3 to 7-membered heterocycloalkyl group can be optionally fused to an aryl or a heteroaryl ring;
each occurrence of R4 is independently —R5, —[C(R12)2]p—R5, —[C(R12)2]pOR5, —[C(R12)2]pOC(O)R5, —[C(R12)2]pN(R10)R5, —[C(R12)2]p-(3 to 7-membered cycloalkyl), —[C(R12)2]p-(3 to 7-membered heterocycloalkyl), —[C(R12)2]p-aryl or —[C(R12)2]p-heteroaryl, wherein said 3 to 7-membered cycloalkyl group, said 3 to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to four R5 groups, such that two R5 groups on different carbon atoms of the same R4 group can combine to form a C1-C3 alkylene group between the carbon atoms to which the two said R5 groups are attached, and wherein said 3 to 7-membered cycloalkyl group and said 3 to 7-membered heterocycloalkyl group can be optionally fused to an aryl or a heteroaryl ring;
each occurrence of R5 is independently H, —[C(R12)2]p-alkyl, —[C(R12)2]p-haloalkyl, —[C(R12)2]p-(3 to 7-membered cycloalkyl), —[C(R12)2]p-(4 to 7-membered heterocycloalkyl), —[C(R12)2]p-aryl, —[C(R12)2]p-heteroaryl, —[C(R12)2]p—C(O)R12—[C(R12)2]pOR10, —[C(R12)2]pOC(O)R12, —[C(R12)2]pN(R10)2, —[C(R12)2]pN(R10), —C(O)R12, —[C(R12)2]pS(O)2R11, —[C(R12)2]pN(R10)S(O)2R11, —[C(R12)2]pS(O)2(R11)N(R10)C(O)—[C(R12)2]qN(R10)2, —C(O)—[(R12)2]qN(R10)C(O)alkyl, —C(O)[C(R12)2]qN(R10)C(O)Oalkyl, —C(O)—[C(R12)2]qN(R10)C(O)Ocycloalkyl, —C(O)—[C(R12)2]qN(R10)S(O)2R11 or —C(S)—[C(R12)2]qN(R10)C(O)R6, such that when an R5 group is attached to a nitrogen atom of an A, D, R1, R2, R3 or R4 group, the R5 group must be joined via one of its carbon or sulfur atoms;
each occurrence of R6 is independently H, —C1-C6 alkyl, halo, —OH, —C1-C6 hydroxyalkyl, —N(R15)2, —CN, —C(O)OH, —C1-C6 haloalkyl, —C(O)—(C1-C6 alkyl), —C(O)OR14, —C(O)N(R15)2, —O—C(O)R14, —O—C(O)N(R15)2, —N(R14)C(O)—(C1-C6 alkyl), —NHSO2—(C1-C6 alkyl), —SO2—(C1-C6 alkyl), —SO2NH—(C1-C6 alkyl), —(C1-C6 alkylene)-O—(C1-C6 alkyl), —(C1-C6 alkylene)-N(R15)2, —(C1-C6 alkylene)-S(O)2—(C1-C6 alkyl), —(C1-C6 alkylene)-R14, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl;
each occurrence of R10 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —[C(R12)2]p-(3 to 7-membered cycloalkyl), —[C(R12)2]p—-(4 to 7-membered heterocycloalkyl), —[C(R12)2]p-aryl, —[C(R12)2]p-heteroaryl, —C1-C6 haloalkyl or —C1-C6 hydroxyalkyl, wherein said 3 to 7-membered cycloalkyl group, said 4 to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to two R13 groups, and wherein two R10 groups that are attached to a common nitrogen atom, together with the nitrogen atom to which they are attached, can join to form a 4 to 7-membered heterocycloalkyl group;
each occurrence of R11 is independently —C1-C6 alkyl, [C(R12)2]p—-(3 to 7-membered cycloalkyl),[C(R12)2]p-(4 to 7-membered heterocycloalkyl), —[C(R12)2]p-aryl, —[C(R12)2]p-heteroaryl, —C1-C6 haloalkyl or —C1-C6 hydroxyalkyl, wherein said C1-C6 alkyl group, said 3 to 7-membered cycloalkyl group, said 4 to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to two R13 groups;
each occurrence of R12 is independently H, halo, —C1-C6 haloalkyl, —CN, —C1-C6 alkyl, —C1-C6 alkylene-OR16, —C1-C6 alkylene-N(R15)2, —C(O)—(C1-C6 alkyl), —C(O)OH, —C(O)N(R15)2, —OR16, —N(R15)2, —NHC(O)—(C1-C6 alkyl), —NHSO2—(C1-C6 alkyl), 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl, wherein said 3 to 7-membered cycloalkyl group, said 4 to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to 3 substituents, which can be the same or different, and are selected from C1-C6 alkyl, halo, —C1-C6 haloalkyl, —C1-C6 hydroxyalkyl, —OH, —C(O)NH—(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —O—(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2 and —NHC(O)—(C1-C6 alkyl), and wherein two geminal R12 groups, together with the common carbon atom to which they are attached, can join to form —C(O)—, —C(S)—, a 3 to 7-membered cycloalkyl group or a 4 to 7-membered heterocycloalkyl group, such that no two adjacent —C(R12)2— groups can join to form a —C(O)—C(O)—, —C(S)—C(S)—, —C(O)—C(S)— or —C(S)—C(O)— group;
each occurrence of R13 is independently H, —C1-C6 haloalkyl, —C1-C6 alkyl, —(C1-C6 alkylene)-O—(C1-C6 alkyl), —C1-C6 hydroxyalkyl, —(C1-C6 alkylene)-NH—(C1-C6 alkyl), —C(O)—(C1-C6 alkyl), —C(O)O(C1-C6 alkyl), —C(O)OH or —C(O)NH—(C1-C6 alkyl);
each occurrence of R14 is independently H, —C1-C6 alkyl, 3 to 6-membered cycloalkyl or 4 to 6-membered heterocycloalkyl;
each occurrence of R15 is independently H, —C1-C6 alkyl, —C1-C6 haloalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl, such that two R15 groups that are attached to a common nitrogen atom, together with the nitrogen atom to which they are attached, can join to form a 4 to 7-membered heterocycloalkyl group;
each occurrence of R16 is independently H, —C1-C6 alkyl, —C1-C6 haloalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl;
each occurrence of R17 is independently H, —C1-C6 alkyl, halo, —C1-C6 haloalkyl, or 3 to 7-membered cycloalkyl;
each occurrence of m is independently an integer ranging from 0 to 2;
each occurrence of n is independently an integer ranging from 0 to 2;
each occurrence of p is independently an integer ranging from 0 to 3; and
each occurrence of q is independently an integer ranging from 1 to 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A and D are each independently heteroaryl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein A and D are each independently selected from
wherein R1 and R3 represent possible substituents on A, and R2 and R4 represent possible substituents on D.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the group:
is selected from:

### Claim 5 (depends on 1)

The compound of claim 1, wherein L1 and L2 are each independently selected from a bond, C2-C4 alkylene, —NH—, —C(O)—, —NHC(O)—, and —S(O)2—.

### Claim 6 (depends on 1)

The compound of claim 1, having the formula:
or a pharmaceutically acceptable salt thereof.
wherein:
A is heteroaryl, which can be optionally and independently substituted on one or more ring carbon atoms with R3;
D is heteroaryl, which can be optionally and independently substituted on one or more ring carbon atoms with R4:
M1 is —CH— or —N—;
M2 is —CH— or —N—;
X1 is —NH— or —O— when the optional and additional bond to X1 is not present, and X1 is —CH— or —N— when the optional and additional bond to X1 is present;
X2 is —CH2—, —NH— or —O— when the optional and additional bond to X2 is not present, and X2 is CH— or N— when the optional and additional bond to X2 is present;
Y1 is —C— when an optional and additional bond to Y1 is present, and Y1 is —CH— when an optional and additional bond to Y1 is absent;
Y2 when an optional and additional bond to Y2 is present, and Y2 is —CH— when an optional and additional bond to Y2 is absent;
Z1 is —CH2— —NH— or —O— when the optional and additional bond to Z1 is not present, and Z1 is —CH— or —N— when the optional and additional bond to Z1 is present;
Z2 is —CH2—, —NH— or —O— when the optional and additional bond to Z2 is not present, and Z2 is —CH— or —N— when the optional and additional bond to Z2 is present;
each occurrence of R3 is independently 3 to 7-membered heterocycloalkyl, which can be optionally and independently substituted with up to four R5 groups, and wherein the 3 to 7-membered heterocycloalkyl group can be optionally fused to an aryl or heteroaryl ring;
each occurrence of is independently 3 to 7-membered heterocycloalkyl, which can be optionally and independently substituted with up to four R5 groups, and wherein the 3 to 7-membered heterocycloalkyl group can be optionally fused to an aryl or a heteroaryl ring;
each occurrence of R5 is independently halo, —C(O)N(R)C(O)N(R10)C(O)N(R10)2, —C(O)C(R12)2N(R10)C(O)R6, or two R5 groups on different carbon atoms of the same R3 or R4 group can combine to form a C1-C3 alkylene group between the carbon atoms to which the two said R5 groups are attached:
each occurrence of R6 is independently —C1-C6 alkyl, —O—(C1-C6 alkyl), —C1-C6 haloalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl;
each occurrence of R10 is independently H or —C1-C6 alkyl; and
each occurrence of R12 is independently H, C1-C6 haloalkyl, —C1-C6 alkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the group:
is selected from:

### Claim 8 (depends on 7)

The compound of claim 7, wherein A and D are each imidazolyl or benzimidazolyl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R3 and R4 are each independently selected from:

### Claim 10 (depends on 9)

The compound of claim 9, wherein R3 and R4 are each:

### Claim 11 (depends on 9)

The compound of claim 9, wherein each occurrence of R5 is independently selected from:

### Claim 12 (depends on 9)

The compound of claim 9, wherein each occurrence of R5 is independently:
wherein Ra is H, alkyl, haloalkyl, cycloalkyl or aryl, and Rb is alkyl.

### Claim 13 (depends on 12)

The compound of claim 12, wherein each occurrence of R5 is:

### Claim 14 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
each occurrence of Rf is independently H or F;
each occurrence of Rg is independently H or F;
A and D are the same and are selected from:
such that the bond adjacent to the nitrogen atoms in A and D are joined to the pyrrolidine ring of formula (Ib);
T is selected from:

### Claim 15 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
each occurrence of Rf is independently H or F;
each occurrence of Rg is independently H or F;
A and D are the same and are selected from:
such that the bond adjacent to the nitrogen atoms in A and D are joined to the pyrrolidine ring of formula (Ic);
L1 is a bond, C2-C4 alkylene, —NH—, —C(O)—, —NHC(O)— or —S(O)2—:
L2 is a bond, C2-C4 alkylene, —NH—, —C(O)—, —C(O)NH— or —S(O)2—, such that at least one of L1 and L2 is other than a bond; and
T is selected from:

### Claim 16

The compound having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.

### Claim 18 (depends on 1, 17)

The composition of claim 17, further comprising at least one additional antiviral agent, which is not a compound of claim 1, wherein the additional antiviral agent(s) is selected from: an HCV polymerase inhibitor; an interferon; a RNA replication inhibitor; an antisense agent; a therapeutic vaccine; a protease inhibitor; an antibody therapy (monoclonal or polyclonal) or ribavirin, and wherein the amounts administered are together effective to treat a viral infection.

### Claim 19 (depends on 1)

A method for treating HCV infection in a patient, the method compriSing administering to the patient an effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1, 19)

The method of claim 19, further comprising administering to the patient at least one additional antiviral agent, which is not a compound of claim 1, wherein the additional antiviral agent(s) is selected from: an HCV polymerase inhibitor; an interferon; a RNA replication inhibitor; an antisense agent; a therapeutic vaccine; a protease inhibitor; an antibody therapy (monoclonal or polyclonal) or ribavirin, and wherein the amounts administered are together effective to treat the HCV infection.

### Claim 21

(canceled)

### Claim 22

(canceled)
